Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus
| Autor: | Sanne Bøjet Larsen, Anne-Mette Hvas, Erik Lerkevang Grove, Steen Dalby Kristensen, S. B. Mortensen |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Platelet Aggregation Coronary Artery Disease Gastroenterology Coronary artery disease Thromboxane A2 chemistry.chemical_compound Internal medicine Diabetes mellitus medicine Humans Platelet Platelet activation Aged Aspirin business.industry Type 2 Diabetes Mellitus Hematology Middle Aged Platelet Activation medicine.disease Thromboxane B2 Endocrinology Diabetes Mellitus Type 2 chemistry Female business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Mortensen, S B, Larsen, S B, Grove, E, Kristensen, S D & Hvas, A-M 2009, ' Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus ', Boston, Massachussets, United States, 13/07/2009-17/07/2009, . Neergaard-Petersen, S A C, Larsen, S B, Grove, E L, Kristensen, S D & Hvas, A-M 2010, ' Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus ', Thrombosis Research, vol. 126, no. 4, pp. e318-22 . https://doi.org/10.1016/j.thromres.2010.03.013 |
| ISSN: | 0049-3848 |
| DOI: | 10.1016/j.thromres.2010.03.013 |
| Popis: | article i nfo Introduction: Diabetes mellitus is complicated by accelerated atherosclerosis, resulting in an increased risk of coronary artery disease (CAD) and thrombosis. Despite the proven benefits of aspirin, previous studies indicate a reduced cardiovascular protection from aspirin in diabetic patients. We aimed to investigate whether diabetes mellitus influenced the platelet response to aspirin in patients with CAD. Materials and Methods: Platelet aggregation and activation were evaluated during aspirin treatment in 85 diabetic and 92 non-diabetic patients with CAD. Adherence to aspirin was carefully controlled. All patients had CAD verified by coronary angiography and were taking 75 mg non-enteric coated aspirin daily. Results: Diabetic patients showed significantly higher levels of platelet aggregation compared to non-diabetic patients evaluated by VerifyNow ® Aspirin (p=0.03) and Multiplate ® aggregometry using arachidonic acid (AA) 0.5 mM (p=0.005) and 1.0 mM (p=0.009). In addition, platelet activation determined by soluble P- selectin was significantly higher in diabetics compared to non-diabetics (p=0.005). The higher AA-induced aggregation was associated with higher levels of HbA1c. Compliance was confirmed by low levels of serum thromboxane B2 (below 7.2 ng/mL). Diabetics had significantly higher levels of serum thromboxane B2 (pb0.0001). Conclusions: Diabetic patients with CAD had significantly higher levels of both platelet aggregation and activation compared to non-diabetic patients with CAD despite treatment with the same dosage of aspirin. These findings may partly explain the reduced cardiovascular protection from aspirin in diabetic patients. © 2010 Elsevier Ltd. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect